Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to improve accessibility to critical cancer therapies while fostering local industry growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/75cGBLe
via IFTTT

Read More

Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal

The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology partnerships and joint ventures. India aims to become a global hub for medical innovation and device development. Hospitals must offer transparent treatment packages and ethical patient care practices. Enhancing interpreter services will improve foreign patient confidence and communication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zIGLUJt
via IFTTT

Read More

Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TNo8DCW
via IFTTT

Read More

'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch

Indian Immunologicals confirmed no counterfeit Abhayrab vaccine batch was exported. Four individuals were arrested by Delhi Police after seizing fake vaccine vials. The manufacturer stated all vaccine batches undergo independent testing and government certification. This ensures vaccines reach patients through regulated and authorized supply chains. Previous counterfeit batches had triggered international health authority alerts for travelers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/njKqvM9
via IFTTT

Read More

Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal

Piyush Goyal emphasized the importance of enhancing India's pharmaceutical industry to draw in more investments. He urged for the creation of robust supply chains to avoid reliance on a single country. The minister also championed the idea of bolstering research and development, securing patents for Indian innovations, and promoting alignment with global regulatory standards. Furthermore, he recommended increasing production in the Ayush sector and medical devices to achieve global recognition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uSMw7cZ
via IFTTT

Read More

Growing peptide trend raises safety concerns among doctors

Doctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines differ from experimental compounds promoted online. Social media influencers and wellness trends encourage experimentation with unapproved injectable peptides. Experts emphasize that "peptide" is a chemical category, not a safety guarantee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH5JXIE
via IFTTT

Read More

RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities

RPG Life Sciences plans to deploy Rs 500 crore over the next 12 months to expand manufacturing and API capabilities through strategic acquisitions, Managing Director Ashok Nair said. The drugmaker has committed Rs 700 crore for expansion and targets Rs 2,000-2,500 crore revenue by 2030, supported by domestic and international growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JQC9k2U
via IFTTT

Read More